The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab

Bullous pemphigoid (BP) is a rare autoimmune blistering condition that predominantly affects the elderly population. Typical treatment regimens target the immune system and inflammatory response. We present a case of BP in a 78-year-old male patient that occurred following the coronavirus disease 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Savoldy, Michelle A, Tadicherla, Teja, Moureiden, Zade, Ayoubi, Noura, Baldwin, Brooke T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675981/
https://www.ncbi.nlm.nih.gov/pubmed/36415388
http://dx.doi.org/10.7759/cureus.30541
_version_ 1784833490650398720
author Savoldy, Michelle A
Tadicherla, Teja
Moureiden, Zade
Ayoubi, Noura
Baldwin, Brooke T
author_facet Savoldy, Michelle A
Tadicherla, Teja
Moureiden, Zade
Ayoubi, Noura
Baldwin, Brooke T
author_sort Savoldy, Michelle A
collection PubMed
description Bullous pemphigoid (BP) is a rare autoimmune blistering condition that predominantly affects the elderly population. Typical treatment regimens target the immune system and inflammatory response. We present a case of BP in a 78-year-old male patient that occurred following the coronavirus disease 2019 (COVID-19) vaccination. This case was refractory to topical steroids and immunosuppressants. However, it responded to treatment with dupilumab, a monoclonal antibody therapy. Dupilumab is classically indicated for the treatment of asthma, eosinophilic esophagitis, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis. We highlight the importance of considering the off-label use of dupilumab and its success in treating BP.
format Online
Article
Text
id pubmed-9675981
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-96759812022-11-21 The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab Savoldy, Michelle A Tadicherla, Teja Moureiden, Zade Ayoubi, Noura Baldwin, Brooke T Cureus Dermatology Bullous pemphigoid (BP) is a rare autoimmune blistering condition that predominantly affects the elderly population. Typical treatment regimens target the immune system and inflammatory response. We present a case of BP in a 78-year-old male patient that occurred following the coronavirus disease 2019 (COVID-19) vaccination. This case was refractory to topical steroids and immunosuppressants. However, it responded to treatment with dupilumab, a monoclonal antibody therapy. Dupilumab is classically indicated for the treatment of asthma, eosinophilic esophagitis, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis. We highlight the importance of considering the off-label use of dupilumab and its success in treating BP. Cureus 2022-10-21 /pmc/articles/PMC9675981/ /pubmed/36415388 http://dx.doi.org/10.7759/cureus.30541 Text en Copyright © 2022, Savoldy et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Savoldy, Michelle A
Tadicherla, Teja
Moureiden, Zade
Ayoubi, Noura
Baldwin, Brooke T
The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab
title The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab
title_full The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab
title_fullStr The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab
title_full_unstemmed The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab
title_short The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab
title_sort successful treatment of covid-19-induced bullous pemphigoid with dupilumab
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675981/
https://www.ncbi.nlm.nih.gov/pubmed/36415388
http://dx.doi.org/10.7759/cureus.30541
work_keys_str_mv AT savoldymichellea thesuccessfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab
AT tadicherlateja thesuccessfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab
AT moureidenzade thesuccessfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab
AT ayoubinoura thesuccessfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab
AT baldwinbrooket thesuccessfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab
AT savoldymichellea successfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab
AT tadicherlateja successfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab
AT moureidenzade successfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab
AT ayoubinoura successfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab
AT baldwinbrooket successfultreatmentofcovid19inducedbullouspemphigoidwithdupilumab

Ejemplares similares